These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9734938)

  • 41. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock.
    Stephens DP; Thomas JH; Higgins A; Bailey M; Anstey NM; Currie BJ; Cheng AC
    Crit Care Med; 2008 Feb; 36(2):448-54. PubMed ID: 18216600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.
    Liu ZM; Chen J; Kou Q; Lin Q; Huang X; Tang Z; Kang Y; Li K; Zhou L; Song Q; Sun T; Zhao L; Wang X; He X; Wang C; Wu B; Lin J; Yuan S; Gu Q; Qian K; Shi X; Feng Y; Lin A; He X; ; Guan XD
    Intensive Care Med; 2018 Nov; 44(11):1816-1825. PubMed ID: 29971593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.
    López A; Lorente JA; Steingrub J; Bakker J; McLuckie A; Willatts S; Brockway M; Anzueto A; Holzapfel L; Breen D; Silverman MS; Takala J; Donaldson J; Arneson C; Grove G; Grossman S; Grover R
    Crit Care Med; 2004 Jan; 32(1):21-30. PubMed ID: 14707556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypothermia and cytokines in septic shock. Norasept II Study Investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock.
    Marik PE; Zaloga GP
    Intensive Care Med; 2000 Jun; 26(6):716-21. PubMed ID: 10945388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
    Suitters AJ; Foulkes R; Opal SM; Palardy JE; Emtage JS; Rolfe M; Stephens S; Morgan A; Holt AR; Chaplin LC
    J Exp Med; 1994 Mar; 179(3):849-56. PubMed ID: 8113678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study.
    Forceville X; Laviolle B; Annane D; Vitoux D; Bleichner G; Korach JM; Cantais E; Georges H; Soubirou JL; Combes A; Bellissant E
    Crit Care; 2007; 11(4):R73. PubMed ID: 17617901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee.
    Sprung CL; Finch RG; Thijs LG; Glauser MP
    Crit Care Med; 1996 Sep; 24(9):1441-7. PubMed ID: 8797613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
    Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
    J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Observations on the role of tumor necrosis factor-alpha in a murine model of shock due to Streptococcus pyogenes.
    Wayte J; Silva AT; Krausz T; Cohen J
    Crit Care Med; 1993 Aug; 21(8):1207-12. PubMed ID: 8339588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
    Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J
    Lancet; 1998 Nov; 352(9140):1586-9. PubMed ID: 9843104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes.
    Martin RA; Silva AT; Cohen J
    FEMS Microbiol Lett; 1993 Jun; 110(2):175-8. PubMed ID: 8349091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Search for effective immunomodulating strategies against sepsis.
    Vincent JL
    Lancet; 1998 Mar; 351(9107):922-3. PubMed ID: 9734931
    [No Abstract]   [Full Text] [Related]  

  • 57. Plasma L-citrulline concentrations and its relationship with inflammation at the onset of septic shock: a pilot study.
    Crenn P; Neveux N; Chevret S; Jaffray P; Cynober L; Melchior JC; Annane D;
    J Crit Care; 2014 Apr; 29(2):315.e1-6. PubMed ID: 24360391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.
    Cross AS; Opal SM; Palardy JE; Bodmer MW; Sadoff JC
    J Infect Dis; 1993 Jan; 167(1):112-8. PubMed ID: 8418157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-ovine interleukin-1beta monoclonal antibody immunotherapy in an ovine model of gram-negative septic shock.
    Peake SL; Pierides J; Leppard PI; Russ GR
    Crit Care Med; 2002 Jan; 30(1):171-81. PubMed ID: 11902259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure.
    Stevens DL; Bryant AE; Hackett SP; Chang A; Peer G; Kosanke S; Emerson T; Hinshaw L
    J Infect Dis; 1996 Mar; 173(3):619-26. PubMed ID: 8627025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.